ALNY vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ALNY dominates in value with a market cap of 38.15 billion USD, eclipsing TEVA’s 18.96 billion USD by roughly 2.01×.
TEVA carries a higher beta at 0.63, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
TEVA is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALNY, which is purely domestic.
Symbol | ALNY | TEVA |
---|---|---|
Company Name | Alnylam Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
Country | US | IL |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Richard D. Francis |
Price | 292.58 USD | 16.55 USD |
Market Cap | 38.15 billion USD | 18.96 billion USD |
Beta | 0.17 | 0.63 |
Exchange | NASDAQ | NYSE |
IPO Date | June 1, 2004 | February 16, 1982 |
ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALNY and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALNY nor TEVA turned a profit—both carry negative P/E ratios of -140.68 and -14.61, underscoring continued losses that pressure their valuations.
- Analysts assign negative forward PEG ratios to both ALNY (-38.16) and TEVA (-1.13), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, TEVA (P/FCF 24.73) indicates positive free cash flow generation.
Symbol | ALNY | TEVA |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | -140.68 | -14.61 |
Forward PEG Ratio (TTM) | -38.16 | -1.13 |
Price-to-Sales Ratio (P/S, TTM) | 16.25 | 1.14 |
Price-to-Book Ratio (P/B, TTM) | 328.68 | 3.00 |
Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 24.73 |
EV-to-EBITDA (TTM) | -251.73 | 23.01 |
EV-to-Sales (TTM) | 16.37 | 2.06 |
EV-to-Free Cash Flow (TTM) | -509.80 | 44.66 |
Dividend Comparison
Neither ALNY nor TEVA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
Symbol | ALNY | TEVA |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- TEVA posts a quick ratio of 0.74, indicating limited coverage of short-term debts from its most liquid assets—while ALNY at 2.98 enjoys stronger liquidity resilience.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while TEVA at 2.71 keeps leverage at a more moderate level.
- ALNY posts a negative interest coverage ratio (-0.79), reflecting an operating loss. TEVA, with its ratio at 0.44, also faces difficulty, as its operating earnings do not cover its interest expenses.
Symbol | ALNY | TEVA |
---|---|---|
Current Ratio (TTM) | 3.04 | 1.03 |
Quick Ratio (TTM) | 2.98 | 0.74 |
Debt-to-Equity Ratio (TTM) | 11.28 | 2.71 |
Debt-to-Assets Ratio (TTM) | 0.31 | 0.44 |
Interest Coverage Ratio (TTM) | -0.79 | 0.44 |